Risk factors for survival and local control in chondrosarcoma of bone

Abstract

We studied 153 patients with non-metastatic chondrosarcoma of bone to determine the risk factors for survival and local tumour control. The minimum follow-up was for five years; 52 patients had axial and 101 appendicular tumours. Surgical treatment was by amputation in 27 and limb-preserving surgery in 126. The cumulative rate of survival of all patients, at 10 and 15 years, was 70% and 63%, respectively; 40 patients developed a local recurrence between 3 and 87 months after surgery and 49 developed metastases. Local recurrence was associated with poor survival in patients with concomitant metastases but not in those without. On multivariate analysis independent risk factors for rates of survival include extracompartmental spread, development of local recurrence and high histological grade. Independent risk factors for local recurrence include inadequate surgical margins and tumour size greater than 10 cm. Location within the body, the type of surgery and the duration of symptoms are of no prognostic significance. Surgical excision with an oncologically wide margin provides the best prospect both for cure and local control in these patients.

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

“…It has been associated with late recurrence and metastasis with reports of tumors recurring over 20 years from initiation of primary treatment. In comparison to conventional chondrosarcoma, which has a 10-year overall survival rate of 60% to 70% [6,7,9], the mesenchymal subtype is believed to portend a worse prognosis [2,14,17]. The 10-year survivorship of mesenchymal chondrosarcoma has been previously reported as ranging from 20% to 67% [3,8,11,14,15,17,18,21] with cohorts comprised of head and neck tumors or of pediatric patients representing the upper end of this spectrum [4,16,23].…”

MicroRNA-100 Resensitizes Resistant Chondrosarcoma Cells to Cisplatin through Direct Targeting of mTOR

“…Chondrosarcoma is the second most frequent primary malignant type of primary bone malignancy after osteosarcoma (Fiorenza et al, 2002). About 30% of skeletal system cancers are chondrosarcomas (Onishi et al, 2011;Van Oosterwijk et al, 2013).…”

Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry

“…Therefore, the evaluation of LCS as an aggressive benign tumour rather than a low-grade malignancy by some authors together with its low metastatic potential [3,5,11] have favoured a less invasive treatment at least in the long bones, i.e. intralesional curettage including the use of local adjuvants such as polymethylmethacrylate (PMMA), pasteurisation or cryosurgery [12][13][14][15].…”